Recent News

• 03.12.2025 - Leerink Partners Global Healthcare Conference 2025
• 03.07.2025 - Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025
• 03.07.2025 - Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025
• 03.06.2025 - Lexicon Pharmaceuticals 4th Quarter 2024 Results Conference Call
• 03.06.2025 - Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
• 03.06.2025 - Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
• 03.04.2025 - Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
• 03.04.2025 - Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
• 03.03.2025 - Lexicon Pharmaceuticals PROGRESS Topline Data Update
• 03.03.2025 - Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

Recent Filings

• 03.07.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.06.2025 - 8-K Current report
• 03.06.2025 - EX-99.1 EX-99.1
• 03.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2025 - 4 Statement of changes in beneficial ownership of securities